Wilson Sonsini Goodrich & Rosati advised Design Therapeutics and Logos Capital on the deal. Design Therapeutics, a biotechnology company developing a platform of gene-targeted chimera small…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
